Regenerative Medicine Program, Department of Physiology and Pathophysiology, Spinal Cord Research Centre, Rady Faculty of Health Sciences University of Manitoba, Winnipeg, Manitoba, Canada.
Department of Human Anatomy and Cell Science, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
Glia. 2018 Mar;66(3):538-561. doi: 10.1002/glia.23264. Epub 2017 Nov 17.
Oligodendroglial cell death and demyelination are hallmarks of neurotrauma and multiple sclerosis that cause axonal damage and functional impairments. Remyelination remains a challenge as the ability of endogenous precursor cells for oligodendrocyte replacement is hindered in the unfavorable milieu of demyelinating conditions. Here, in a rat model of lysolecithin lysophosphatidyl-choline (LPC)-induced focal demyelination, we report that Neuregulin-1 (Nrg-1), an important factor for oligodendrocytes and myelination, is dysregulated in demyelinating lesions and its bio-availability can promote oligodendrogenesis and remyelination. We delivered recombinant human Nrg-1β1 (rhNrg-1β1) intraspinally in the vicinity of LPC demyelinating lesion in a sustained manner using poly lactic-co-glycolic acid microcarriers. Availability of Nrg-1 promoted generation and maturation of new oligodendrocytes, and accelerated endogenous remyelination by both oligodendrocyte and Schwann cell populations in demyelinating foci. Importantly, Nrg-1 enhanced myelin thickness in newly remyelinated spinal cord axons. Our complementary in vitro studies also provided direct evidence that Nrg-1 significantly promotes maturation of new oligodendrocytes and facilitates their transition to a myelinating phenotype. Nrg-1 therapy remarkably attenuated the upregulated expression chondroitin sulfate proteoglycans (CSPGs) specific glycosaminoglycans in the extracellular matrix of demyelinating foci and promoted interleukin-10 (IL-10) production by immune cells. CSPGs and IL-10 are known to negatively and positively regulate remyelination, respectively. We found that Nrg-1 effects are mediated through ErbB2 and ErbB4 receptor activation. Our work provides novel evidence that dysregulated levels of Nrg-1 in demyelinating lesions of the spinal cord pose a challenge to endogenous remyelination, and appear to be an underlying cause of myelin thinning in newly remyelinated axons.
少突胶质细胞死亡和脱髓鞘是神经创伤和多发性硬化症的标志,导致轴突损伤和功能障碍。由于内源性前体细胞在脱髓鞘条件下的不利环境中,对少突胶质细胞的替代能力受到阻碍,因此重新髓鞘化仍然是一个挑战。在这里,我们在溶卵磷脂溶血磷脂酰胆碱 (LPC) 诱导的局灶性脱髓鞘大鼠模型中报告,神经调节蛋白 1 (Nrg-1),一种对少突胶质细胞和髓鞘形成很重要的因素,在脱髓鞘病变中失调,其生物利用度可以促进少突胶质细胞发生和髓鞘形成。我们使用聚乳酸-共-羟基乙酸微载体以持续的方式在 LPC 脱髓鞘病变附近鞘内递重组人 Nrg-1β1 (rhNrg-1β1)。Nrg-1 的可用性促进了新的少突胶质细胞的生成和成熟,并加速了脱髓鞘病灶中少突胶质细胞和施万细胞群体的内源性髓鞘形成。重要的是,Nrg-1 增强了新髓鞘化脊髓轴突中的髓鞘厚度。我们的互补体外研究也提供了直接证据,表明 Nrg-1 显著促进新的少突胶质细胞的成熟,并促进它们向髓鞘形成表型的转变。Nrg-1 治疗显著减弱了脱髓鞘病灶中细胞外基质中软骨素硫酸盐蛋白聚糖 (CSPGs) 特异性糖胺聚糖的上调表达,并促进了免疫细胞中白细胞介素 10 (IL-10) 的产生。CSPGs 和 IL-10 分别已知负调节和正调节髓鞘形成。我们发现 Nrg-1 作用是通过 ErbB2 和 ErbB4 受体激活介导的。我们的工作提供了新的证据,表明脊髓脱髓鞘病变中 Nrg-1 水平的失调对内源性髓鞘形成构成挑战,并且似乎是新髓鞘化轴突中髓鞘变薄的潜在原因。